Cencora, Inc. (NYSE:COR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports.

It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...

We note that Cencora, Inc. (NYSE:COR) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. Debt is a tool to help businesses grow ...

Fisher Asset Management LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 17.7% during the 4th quarter, according to its most recent 13F filing with the SEC.

Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

SYDNEY--(BUSINESS WIRE)--Boomi™, the intelligent integration and automation leader, today announced that the University of Technology Sydney (UTS) has used the Boomi Enterprise Platform to ...

Cencora COR has outperformed the market over the past 5 years by 8.2% on an annualized basis producing an average annual return of 20.8%. Currently, Cencora has a market capitalization of $47.04 ...